PYPD PolyPid Ltd.

Biotech Analyst Ratings

Latest News

1. 11 May 2022 PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results

   •  Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Abdominal Soft Tissue Surgery Expected to Occur Imminently

   •  Recruitment Progressing as Planned with Approximately 900 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Abdominal Soft Tissue Surgery

   •  Extended Cash Runway into the Second Quarter of 2023 with $15 million Non-Dilutive Secured Term Loan Facility

   •  Strengthened Executive Management Team
   

   •  Conference Call Scheduled for Today at 8:30 AM ET

   PETACH TIKVA, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results…

   View Full Article
2. 27 April 2022 PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022

   PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 11, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
   

   Conference Call Dial-In & Webcast Information:

   Date:	Wednesday, May 11, 2022
   Time:	8:30 AM Eastern Time
   United States:	+1 877-870-9135
   Israel:	+972 1809 213-985
   International:	+44 (0) 2071 928338
   Conference ID:	3450787
   Webcast:	https://edge.media-server.com/mmc/p/djs2mjt6

   …

   View Full Article
3. 25 April 2022 PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine

   Presentation evaluates the effect of D-PLEX₁₀₀ in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients
   

   PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the 13th European and Global CLINAM Summit for Nanomedicine, being held virtually on May 2–4, 2022. The focus of this year's summit is From Hope to Product – The Brilliant Prospect in Nanomedicine and Related Fields.

   Dr. Noam Emanuel, Chief Scientific Officer of PolyPid, will present the abstract, ‘From Bench to Bedside: D-PLEX₁₀₀ Limits AMR Occurrence in Randomized …

   View Full Article
4. 12 April 2022 PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting

   PETACH TIKVA, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the upcoming Surgical Infection Society (SIS) 2022 Annual Meeting, being held on April 23-26, 2022 in Dallas, TX.

   The abstract, ‘Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation,' evaluates the addition of D-PLEX₁₀₀ to the surgical site infection standard of care prophylaxis regimen in elective colorectal surgery. The presentation will include an oral review led by Dr. Anthony Senagore, Senior Medical Director of PolyPid, and will be…

   View Full Article
5. 06 April 2022 PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility

   PETACH TIKVA, Israel, April 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company has entered into a secured loan agreement for up to $15 million with Kreos Capital VI (Expert Fund) LP ("Kreos"). Proceeds from the loan will be used to support global commercialization preparations for the launch of D-PLEX₁₀₀ for the prevention of abdominal soft tissue surgical site infections (SSIs), as well as further advancement of PolyPid's OncoPLEX development platform and general corporate purposes.
   

   "This loan facility broadens our financing options and provides us with access, on a non-dilutive basis, to significant additional…

   View Full Article